Glenmark and SaNOtize announce positive Results from Phase 3 Clinical Trial of NONS (FabiSpray®) in Non-Hospitalized Adult Indian Patients with COVID-19
Phase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94% in 24 hours and 99% in 48 hours. NONS was safe and well tolerated in COVID-19 patients. Glenmark received manufacturing and marketing approval from India’s drug regulator for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval […]
